These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33184461)

  • 1. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients.
    Kida D; Takahashi N; Kaneko A; Hirano Y; Fujibayashi T; Kanayama Y; Hanabayashi M; Yabe Y; Takagi H; Oguchi T; Kato T; Funahashi K; Matsumoto T; Ando M; Kuwatsuka Y; Tanaka E; Yasuoka H; Kaneko Y; Hirata S; Murakami K; Sobue Y; Nishiume T; Suzuki M; Yokota Y; Terabe K; Asai S; Ishiguro N; Kojima T
    Sci Rep; 2020 Nov; 10(1):19717. PubMed ID: 33184461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
    Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
    Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.
    Alemao E; Postema R; Elbez Y; Mamane C; Finckh A
    Clin Exp Rheumatol; 2020; 38(3):455-466. PubMed ID: 31770089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
    Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
    Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
    Kubo S; Nakano K; Nakayamada S; Hirata S; Fukuyo S; Sawamukai N; Saito K; Tanaka Y
    Clin Exp Rheumatol; 2016; 34(5):834-841. PubMed ID: 27607196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
    Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
    J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
    Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA
    Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of cumulative anti-cyclic citrullinated protein antibodies with radiographic progression in patients with rheumatoid arthritis.
    Joo YB; Park YJ; Park KS; Kim KJ
    Clin Rheumatol; 2019 Sep; 38(9):2423-2432. PubMed ID: 31049760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan.
    Endo Y; Koga T; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Eguchi M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
    Scand J Rheumatol; 2020 Jan; 49(1):13-17. PubMed ID: 31402744
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
    Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
    Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
    Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI).
    Misaki K; Tamura N; Azuma T; Shinoda K; Tanaka M; Fujiwara H; Tsuboi H; Kasama T; Yoshimi R; Hanyu T; Kusaka Y; Hirao M; Onishi M; Uchino A; Izumiyama T; Yang KS; Ogawa N; Matsui K; Kurasawa K; Kawaai S; Yasuoka H; Okumura N; Ueda Y; Tanaka E; Inoue E; Tsuritani K; Matsumoto S; Yamanaka H; Harigai M
    Mod Rheumatol; 2024 Feb; 34(2):297-306. PubMed ID: 37233722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
    Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
    Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
    Park SH; Han X; Lobo F; Kratochvil D; Patel D
    J Med Econ; 2020 Jun; 23(6):624-630. PubMed ID: 32075453
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting joint destruction in rheumatoid arthritis with power Doppler, anti-citrullinated peptide antibody, and joint swelling.
    Kirino Y; Hama M; Takase-Minegishi K; Kunishita Y; Kishimoto D; Yoshimi R; Asami Y; Ihata A; Oba MS; Tsunoda S; Ohno S; Ueda A; Takeno M; Ishigatsubo Y
    Mod Rheumatol; 2015; 25(6):842-8. PubMed ID: 25736364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study.
    Boman A; Brink M; Lundquist A; Hansson M; Mathsson-Alm L; Rönnelid J; Berglin E; Holmdahl R; Skriner K; Serre G; Klareskog L; Rantapää-Dahlqvist S
    RMD Open; 2019; 5(2):e000946. PubMed ID: 31565241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
    Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Marcelli C; Bardin T; Pane I; Baron G; Mariette X
    Ann Rheum Dis; 2012 Nov; 71(11):1815-9. PubMed ID: 22615458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.